Budget 2026–27 announcement of "Biopharma Shakti" to catalyse India's global role in the next industrial revolution and also establish India as a global biomanufacturing hub: Dr. Jitendra Singh

1. At a Glance

• Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology & Innovation — a ₹10,000-crore scheme announced in the Union Budget 2026–27 to make India a global biomanufacturing hub [1][3][5].
• Pushes India "beyond conventional pharma" into the next industrial phase (biologics, biosimilars, precision biotherapeutics) and complements the BioE3 Policy, 2024 [1][6].
• Announced by MoS (IC) Science & Technology, Dr. Jitendra Singh; rides alongside Budget 2026-27 announcements on four mega-telescope facilities, ₹20,000-crore carbon-capture support, SHANTI Act nuclear duty alignment, and National Geospatial Mission [1].

2. Why in the News

• Union Budget 2026–27 (1 Feb 2026) proposed Biopharma SHAKTI with a ₹10,000 crore outlay over 5 years [1][3][5].
• Centre subsequently constituted an inter-ministerial panel headed by Manoj Joshi, Secretary, Department of Pharmaceuticals, to design & monitor the scheme [3].

3. Background & Evolution

• 2022: India's bioeconomy crosses USD 100 bn; National Biotech Development Strategy lays groundwork.
• Aug 2024: Cabinet approves BioE3 Policy (Biotechnology for Economy, Environment & Employment) — parent framework for "high-performance biomanufacturing"; introduces BioEnablers = Bio-AI Hubs, Biofoundries, Biomanufacturing Hubs [6].
• 2025: DBT–BIRAC joint call for मूलांकुर (Moolankur) Bioenablers proposals under BioE3 [6].
• Feb 2026: Biopharma SHAKTI announced in Budget 2026-27 as a dedicated financial instrument operationalising the biologics arm of BioE3 [1][5].

4. Core Static Facts

• Full form: Strategy for Healthcare Advancement through Knowledge, Technology & Innovation [5].
• Outlay: ₹10,000 crore over 5 years [1][3].
• Nodal ministries: Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers) for SHAKTI implementation; aligned with Department of Biotechnology (Ministry of S&T) running BioE3 [3][6].
• Inter-ministerial panel chair: Secretary, Department of Pharmaceuticals (Manoj Joshi) [3].
• Target market share: ~5% of the global biopharmaceutical market [2].
• Key deliverables [2][3]:
• 3 new NIPERs + upgradation of 7 existing NIPERs.
• 1,000+ accredited clinical trial sites ("India Clinical Trials" network).

• CDSCO capacity-building via a dedicated scientific review cadre.

• Focus products: biologics, biosimilars, precision biotherapeutics (cell & gene therapy, mRNA, monoclonal antibodies) [2][6].

• India's current standing: among top-10 global bioeconomies, top-3 in Asia-Pacific [2].

5. Multi-Dimensional Analysis

Economic

• Scales domestic biologics manufacture to capture 5% of a market dominated by US/EU; reduces import dependence on high-value biosimilars [2].
• Embeds India deeper into pharma global value chains (already the "pharmacy of the world" in generics) [2].

Scientific / Technological

• Bridges lab-to-market gap via biofoundries and Bio-AI hubs (BioE3) [6].
• CDSCO modernisation aligns Indian approval timelines with US-FDA/EMA standards [2].

Social / Health

• 1,000-site clinical trial network broadens patient access and diversifies trial demographics [2].
• Strengthens healthcare security post-COVID supply-shock lessons [2].

Administrative / Governance

• Inter-ministerial panel structure (DoP + DBT + MoHFW + DST) addresses traditional silo problem in biotech-pharma overlap [3].
• Builds on public-private co-creation model of BioE3 [6].

Environmental

• BioE3 umbrella prioritises bio-based chemicals, biopolymers, carbon capture & utilisation — aligning biomanufacturing with net-zero (2070) goals [6].

6. Recent Developments (last 12-18 months)

• Aug 2024: BioE3 Policy approved by Cabinet [6].
• 2025: DBT–BIRAC Moolankur call for biofoundries/biomanufacturing hubs; Assam becomes first state to sign MoU with DBT under BioE3 [6].
• 1 Feb 2026: Biopharma SHAKTI announced in Budget [1].
• Feb–Mar 2026: Inter-ministerial panel constituted under Secretary, DoP, to operationalise scheme [3].
• Companion Budget 2026-27 S&T pushes (Jitendra Singh): four mega telescopes (incl. National Large Solar Telescope, National Large Optical-Infrared Telescope); ₹20,000-crore carbon capture support; SHANTI Act–aligned nuclear import duty exemptions; National Geospatial Mission [1].

7. Prelims Hooks

• Biopharma SHAKTI expands to Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [5].
• Outlay = ₹10,000 crore, duration 5 years, announced in Union Budget 2026-27 [1][3].
• Nodal implementing department: Department of Pharmaceuticals (not DBT) [3].
• Inter-ministerial panel headed by Secretary, Department of Pharmaceuticals [3].
• Scheme targets 5% share of global biopharma market [2].
• Plans 3 new + 7 upgraded NIPERs [2].
• Plans 1,000+ accredited clinical trial sites [2].
• Strengthens CDSCO (regulator under Directorate General of Health Services, MoHFW) [2].
• Parent policy: BioE3 Policy, approved by Cabinet in August 2024; full form: Biotechnology for Economy, Environment & Employment [6].
• BioE3 BioEnablers = Bio-AI Hubs, Biofoundries, Biomanufacturing Hubs [6].
• BioE3 thematic areas include smart proteins, mRNA therapeutics, marine & space biotech [6].
• DBT–BIRAC call branded "मूलांकुर" (Moolankur) for Bioenablers [6].
• India ranks among top 10 global bioeconomies, top 3 in Asia-Pacific [2].
• Companion Budget 2026 science items: ₹20,000-crore carbon capture, SHANTI Act nuclear duty exemptions, National Geospatial Mission, National Large Solar Telescope [1].

8. Mains Relevance

• GS-III: Science & Technology — developments and applications; Indian economy — issues of growth, employment; Government Budgeting.
• GS-II: Government schemes & welfare; Health sector governance.
• Probable stems: 1. "Biopharma SHAKTI complements but does not duplicate the BioE3 Policy." Discuss in light of India's ambition to be a global biomanufacturing hub. 2. Examine how regulatory modernisation (CDSCO, NIPERs, clinical trial sites) is central to translating biotechnology R&D into manufacturing scale in India. 3. India aspires to capture 5% of the global biopharma market by the early 2030s. Discuss the enabling ecosystem and the constraints.

9. Related Topics to Study Next

• BioE3 Policy, 2024 — direct parent framework [6].
• PLI Scheme for Pharmaceuticals & Bulk Drugs — manufacturing complementarity.
• National Biotechnology Development Strategy (NBDS) — long-term policy spine.
• CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulatory backbone.
• NIPERs (National Institutes of Pharmaceutical Education & Research) — human-capital arm.
• BIRAC (Biotechnology Industry Research Assistance Council) — funding vehicle.
• Genome India Programme — precision medicine linkage.
• SHANTI Act / National Geospatial Mission / Carbon Capture Mission — Budget 2026-27 S&T basket [1].

10. Common Errors / Trap Areas

• Wrong ministry: Biopharma SHAKTI is implemented by Department of Pharmaceuticals, not DBT or MoHFW; DBT runs the parent BioE3 [3][6].
• Confusing the acronyms: BioE3 ≠ Biopharma SHAKTI; BioE3 (2024) is policy umbrella, SHAKTI (2026) is the budgetary scheme.
• Misreading "SHAKTI": Stands for Strategy for Healthcare Advancement through Knowledge, Technology & Innovation — not "Shakti" energy/electricity scheme [5].
• CDSCO comes under Directorate General of Health Services, Ministry of Health & Family Welfare — not under Department of Pharmaceuticals.
• BioE3 was approved by Cabinet in August 2024, not in a Budget speech.